Focus: Palatin Technologies is a public-stage small-molecule biotech focused on rare and specialty indications across ophthalmology, cardiovascular, respiratory, nephrology, and immunology. The company operates as a lean R&D organization with minimal commercial revenue and a diversified pipeline.
Profile data last refreshed 6h ago · AI intelligence enriched 2mo ago
No open roles listed right now. Follow Palatin Technologies to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Palatin Technologies's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Help build intelligence for Palatin Technologies
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Palatin Technologies Inc. (PTN) Peer Comparison – Compare with Others - Value Research
Palatin Technologies Inc. (PTN) Peer Comparison – Compare with Others Value Research
StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat It - finance.yahoo.com
StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat It finance.yahoo.com
8-K Filing: PALATIN TECHNOLOGIES INC (PTN) (CIK 0000911216) — 8-K
8-K
What the $10B Crinetics Deal & $2.9B Soleno Acquisition Might Say About Palatin’s Rare-Obesity Opportunity - TradingView
What the $10B Crinetics Deal & $2.9B Soleno Acquisition Might Say About Palatin’s Rare-Obesity Opportunity TradingView
PTN Stock Price and Chart — NASDAQ:PTN - TradingView
PTN Stock Price and Chart — NASDAQ:PTN TradingView
Palatin Technologies stock (US69608A1088): move to Nasdaq puts biotech in the spotlight - AD HOC NEWS
Palatin Technologies stock (US69608A1088): move to Nasdaq puts biotech in the spotlight AD HOC NEWS
Showing 6 of 8 news items
No open positions listed yet. Check their careers page directly.
Recent peer-reviewed publications with author affiliations at this company
Efficacy and Safety of the Melanocortin Pan-Agonist PL9643 in a Phase 2 Study of Patients with Dry Eye Disease.
A novel oral formulation of the melanocortin-1 receptor agonist PL8177 resolves inflammation in preclinical studies of inflammatory bowel disease and is gut restricted in rats, dogs, and humans.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo